Anti-spike IgA and anti-spike IgG peaked in naive individuals at month 1 after second dose administration, whereas in individuals who have recovered from COVID-19, they reached the highest levels after the first injection and remained stable up to month 1 (Figure 1, B and C, left and middle). The gene discussed is CD79A; the disease is COVID-19.